

Rubicon Announces CEO Appointment



13 September 2019 – Rubicon’s Chairman, Dave Knott, announced the appointment of Andrew Baum as the CEO of the Rubicon Group.

Andrew joined Rubicon’s subsidiary ArborGen Inc in March 2012 as president and chief executive officer. During Mr Baum’s 30-year career in the technology industry, he has served as the president and chief executive officer of Sembiosys Genetics Inc, taking the company from a university-based research initiative to a fully integrated, publicly traded biotechnology. His career has also included working in increasing levels of responsibility for Calgene, Inc, becoming president of the oils division in 1992. Following Calgene’s sale to Monsanto, he served as the director of business development, sustainable development sector.

Andrew has a BS in Industrial Engineering and Operations Research from the University of California, Berkeley.

END